Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
496 studies found for:    Open Studies | "Pancreatic Neoplasms"
Show Display Options
Rank Status Study
21 Unknown  Weekly Dosing of an Integrative Chemotherapy Combination to Treat Advanced Pancreatic Cancer
Conditions: Adenocarincoma of Pancreas;   Stage III Pancreatic Cancer;   Stage IVA Pancreatic Cancer;   Stage IVB Pancreatic Cancer
Interventions: Drug: paclitaxel;   Drug: oxaliplatin;   Drug: leucovorin;   Drug: 5-fluorouracil;   Drug: glutathione;   Drug: calcium and magnesium;   Procedure: Chemotherapy;   Procedure: Chemoprotection;   Procedure: Complementary and alternative therapy
22 Recruiting Efficacy and Feasibility of Combining FOLFIRINOX and Stereotactic Radiotherapy for Patients With Irresectable Locally Advanced Pancreatic Cancer.
Condition: Pancreatic Neoplasms
Intervention: Radiation: stereotactic radiotherapy
23 Recruiting A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer
Conditions: Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Drug: Vantictumab;   Drug: Nab-Paclitaxel;   Drug: Gemcitabine
24 Recruiting Dose Escalation Study of OMP-54F28 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer
Conditions: Pancreatic Cancer;   Stage IV Pancreatic Cancer
Intervention: Drug: OMP-54F28, Nab-Paclitaxel and Gemcitabine
25 Recruiting Anti-CD3 x Anti-Erbitux® Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer)
Conditions: Colorectal Cancer;   Cancer of Pancreas;   Pancreatic Neoplasm;   Malignant Neoplasm of Large Intestine;   Malignant Tumor of Colon;   Colon Carcinoma;   Cancer of Colon;   Pancreatic Cancer
Interventions: Drug: FOLFOX6;   Biological: EGFRBi armed ATC Infusions
26 Recruiting Study to Evaluate Bi-weekly Dosing of Gemcitabine Plus Nab-Paclitaxel to Treat Metastatic Pancreatic Cancer
Conditions: Pancreatic Carcinoma Non-resectable;   Stage IV Pancreatic Cancer
Interventions: Drug: Gemcitabine;   Drug: nab-Paclitaxel
27 Unknown  Tomotherapy in Locally Advanced Gallbladder and Pancreatic Cancers
Condition: Gallbladder Neoplasms and Pancreatic Neoplasms
Intervention: Radiation: Tomotherapy
28 Unknown  Role of Cyberknife Stereotactic Radiation Therapy (SBRT) Followed by Gemcitabine for Patients With Locally Advanced Pancreatic Cancer
Conditions: Pancreatic Cancer;   Unresectable Pancreatic Cancer
Intervention: Radiation: stereotactic body radiotherapy
29 Recruiting Combination Chemotherapy With or Without Oregovomab Followed By Stereotactic Body Radiation Therapy and Nelfinavir Mesylate in Treating Patients With Locally Advanced Pancreatic Cancer
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage IA Pancreatic Cancer;   Stage IB Pancreatic Cancer;   Stage IIA Pancreatic Cancer;   Stage IIB Pancreatic Cancer;   Stage III Pancreatic Cancer
Interventions: Drug: gemcitabine hydrochloride;   Drug: leucovorin calcium;   Biological: oregovomab;   Drug: nelfinavir mesylate;   Radiation: stereotactic body radiation therapy;   Procedure: therapeutic conventional surgery;   Other: laboratory biomarker analysis;   Drug: fluorouracil
30 Recruiting Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery
Conditions: Duct Cell Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Biological: ipilimumab;   Drug: gemcitabine hydrochloride;   Other: laboratory biomarker analysis
31 Recruiting Metformin Hydrochloride in Treating Patients With Pancreatic Cancer That Can be Removed by Surgery
Conditions: Stage IA Pancreatic Cancer;   Stage IB Pancreatic Cancer;   Stage IIA Pancreatic Cancer;   Stage IIB Pancreatic Cancer
Interventions: Drug: metformin hydrochloride;   Other: pharmacological study
32 Recruiting Combination Therapy With NC-6004 and Gemcitabine Versus Gemcitabine Alone in Pancreatic Cancer
Conditions: Locally Advanced Pancreatic Cancer;   Metastatic Pancreatic Cancer
Interventions: Drug: NC-6004;   Drug: Gemcitabine
33 Recruiting Analgesia and Pancreatic Cancer Surgery
Condition: Pancreatic Neoplasms
Interventions: Procedure: Epidural patient controlled analgesia;   Drug: Intravenous patient controlled analgesia
34 Unknown  Expression of Inflammatory Proteins in Pancreatic Cancer
Condition: Pancreatic Neoplasms
Intervention: Behavioral: Expression type
35 Recruiting Gemcitabine, Ascorbate, Radiation Therapy for Pancreatic Cancer, Phase I
Condition: Pancreatic Neoplasms
Interventions: Drug: Ascorbate;   Drug: Gemcitabine;   Radiation: Radiation therapy
36 Unknown  Three New Methods for Diagnosing Pancreas Cancer
Condition: Pancreas Cancer
Intervention: Procedure: Ultrasound and contrast agent
37 Recruiting Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic Cancer
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: alisertib;   Drug: gemcitabine
38 Recruiting Integrating Palliative Care and Modern Palliative Care Tools Into the Care of Patients With Pancreas Cancer
Condition: Pancreas Cancer
Intervention: Other: Palliative care with decision aids
39 Recruiting Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Stage I Pancreatic Cancer;   Stage IIA Pancreatic Cancer;   Stage IIB Pancreatic Cancer
Interventions: Drug: oxaliplatin;   Drug: leucovorin calcium;   Drug: irinotecan hydrochloride;   Drug: fluorouracil;   Procedure: therapeutic conventional surgery;   Other: laboratory biomarker analysis
40 Recruiting Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed By Surgery
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Drug: dinaciclib;   Drug: Akt inhibitor MK2206;   Other: pharmacological study;   Other: laboratory biomarker analysis

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years